{"id":57109,"date":"2024-02-27T17:24:41","date_gmt":"2024-02-27T17:24:41","guid":{"rendered":"https:\/\/medsname.com\/flucort-skin-cream\/"},"modified":"2026-05-01T10:49:13","modified_gmt":"2026-05-01T10:49:13","slug":"flucort-skin-cream","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/flucort-skin-cream\/","title":{"rendered":"Flucort Skin Cream"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Flucort Skin Cream?<\/h3>\n

Flucort Skin Cream<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 fluocinolone acetonide 0.025%<\/strong> as a topical cream from Sun Pharma — a potent topical corticosteroid<\/strong> (UK Class III \/ US Class III) used for the short-term treatment of inflammatory and steroid-responsive skin conditions including eczema (atopic dermatitis), psoriasis, contact dermatitis, lichen planus, discoid lupus, seborrhoeic dermatitis<\/strong>, and other dermatoses where topical steroid therapy is indicated. Apply a thin film once or twice daily<\/strong> to affected areas; use the fingertip-unit (FTU) rule<\/strong> for accurate dosing. Maximum continuous course typically 2-4 weeks without medical supervision<\/strong>; longer courses require dermatology input and a planned step-down. Do NOT apply to the face, eyelids, armpits, groin, or genital area<\/strong> for more than a few days — thin-skin areas have much higher absorption and risk of steroid atrophy \/ telangiectasia \/ perioral dermatitis. \u03a3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2:<\/strong> mild local burning or itching, skin thinning with prolonged use, telangiectasia, hypopigmentation. Tacrolimus or pimecrolimus<\/strong> (topical calcineurin inhibitors) are the steroid-sparing alternatives for thin-skin areas and long-term maintenance.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Flucort Skin Cream?<\/h2>\n

Flucort Skin Cream is a topical fluocinolone acetonide 0.025%<\/strong> cream from Sun Pharma, supplied in a 20 g tube. fluocinolone acetonide is a synthetic glucocorticoid (corticosteroid) classified as UK Class III \/ US Class III<\/strong> on the topical-steroid potency ladder.<\/p>\n

Topical Steroid Potency — Where Flucort Skin Cream Sits<\/h2>\n

Topical corticosteroids are categorised by potency. Flucort Skin Cream is in the potent<\/strong> tier:<\/p>\n\n\n\n\n\n\n\n\n
UK Class<\/th>\nUS Class<\/th>\nPotency tier<\/th>\nExamples<\/th>\n<\/tr>\n<\/thead>\n
I (mild)<\/td>\nVII<\/td>\nMild<\/td>\nHydrocortisone 0.5-1%<\/td>\n<\/tr>\n
II<\/td>\nVI-V<\/td>\n\u039c\u03ad\u03c4\u03c1\u03b9\u03bf<\/td>\nClobetasone butyrate, betamethasone valerate 0.025%<\/td>\n<\/tr>\n
III<\/td>\nIII-II<\/td>\nPotent<\/td>\nFluticasone propionate 0.05%, fluocinolone acetonide 0.025%, mometasone 0.1%, betamethasone valerate 0.1%<\/strong><\/td>\n<\/tr>\n
IV<\/td>\nI<\/td>\nVery potent<\/td>\nClobetasol propionate 0.05% (Tenovate, Dermovate)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Use the lowest potency that controls the condition. Step down to a milder steroid (or to a non-steroidal option like a topical calcineurin inhibitor) as soon as the flare is controlled.<\/p>\n

How Flucort Skin Cream Works<\/h2>\n

fluocinolone binds to intracellular glucocorticoid receptors in keratinocytes, dermal fibroblasts, and infiltrating inflammatory cells. The activated receptor translocates to the nucleus where it suppresses transcription of pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α), inhibits phospholipase A2<\/sub> (reducing prostaglandin and leukotriene synthesis), and promotes apoptosis of T-lymphocytes infiltrating the inflamed skin. The result is rapid suppression of the inflammatory cascade driving conditions like eczema and psoriasis.<\/p>\n

Onset of clinical effect: within 24-48 \u03ce\u03c1\u03b5\u03c2<\/strong>; full response usually within 1-2 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2<\/strong> at the right potency.<\/p>\n

\u0395\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n